RxDoctor Payments Data

Melissa Odorisio, PA

Physician Assistant · Greenville, SCNPI 1801105952

Payments from drug & device makers

$1,585in general payments, 2019–2025

Across 86 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$572
  • Novo Nordisk$223
  • Lilly USA, LLC$162
  • AstraZeneca$144
  • Dexcom, Inc.$141
  • Insulet Corporation$120
  • plus $223 from 9 others

What the payments were for

  • Food & beverage$1,585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,585 in reported general payments places this provider in the 70th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$116,865
Medicare patients
557
Services billed
3,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$190,831
JardianceEmpagliflozin70$88,536
MounjaroTirzepatide50$66,683
RybelsusSemaglutide27$48,171
Tresiba Flextouch U-100Insulin Degludec55$26,891
TrulicityDulaglutide17$23,242
FarxigaDapagliflozin Propanediol18$20,412
Tresiba Flextouch U-200Insulin Degludec18$20,063
EliquisApixaban17$17,641
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$14,551
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$8,525
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$6,170
Humalog Kwikpen U-100Insulin Lispro24$5,875
Novolog FlexpenInsulin Aspart18$4,809
Nano 2nd Gen Pen NeedlePen Needle, Diabetic50$3,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$223$240,538201 claims
Lilly USA, LLCMounjaro, Trulicity$162$89,92567 claims
Boehringer IngelheimJardiance$14$88,53670 claims
AstraZenecaFarxiga$144$20,41218 claims
PfizerEliquis$14$17,64117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →